Verastem: Maintaining "Buy" As 1st Half 2026 Catalysts In Play (NASDAQ:VSTM)

Group 1 - The article discusses Verastem (VSTM) and its recent challenges, particularly the setback in targeting KRAS G12C NSCLC through the RAMP-203 trial [2] - The author, Terry Chrisomalis, has extensive experience in the biotech sector and provides in-depth analysis of pharmaceutical companies through the Biotech Analysis Central service [2] - The Biotech Analysis Central service includes a library of over 600 biotech investing articles and a model portfolio of more than 10 small and mid-cap stocks [2] Group 2 - The article does not provide any specific financial data or performance metrics related to Verastem or the biotech industry [1][3][4]